Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Multiple combinational strategies of immunotherapy for esophageal squamous cell carcinoma: One institutional experience in Taiwan since 2016.
Authors
Jo-Pai Chen
Yun-lin Branch, National Taiwan Univeristy Hospital, Taipei, Taiwan
Jo-Pai Chen , Wei-Chen Lu , Hsu Wu , Tsui-Mai Kao , Keng-Man Chiang , Hsing-wu Chen , Sung-Hsin Kuo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
DOI
10.1200/JCO.2022.40.4_suppl.328
Abstract #
328
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.
First Author: Zeynep Eroglu
Poster
2024 ASCO Annual Meeting
High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.
First Author: Ahmad A. Tarhini
Poster
2024 ASCO Annual Meeting
Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL).
First Author: Charlee Nardin
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Initial findings from the DREAM-GI national database: Assessing the efficacy and safety of neoadjuvant immunotherapy (NIT) in patients with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) gastrointestinal (GI) cancer.
First Author: Sakti Chakrabarti